Anne Yagolovich - Search Results

Year	Number of Results
2007	1
2009	1
2020	1
2021	3
2022	4
2023	5
2024	2

1

Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor Pathway.

Yagolovich AV, Gasparian ME, Dolgikh DA. Yagolovich AV, et al. Pharmaceutics. 2023 Feb 3;15(2):515. doi: 10.3390/pharmaceutics15020515. Pharmaceutics. 2023. PMID: 36839837 Free PMC article. Review.

2

DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma.

Yagolovich AV, Isakova AA, Artykov AA, Vorontsova YV, Mazur DV, Antipova NV, Pavlyukov MS, Shakhparonov MI, Gileva AM, Markvicheva EA, Plotnikova EA, Pankratov AA, Kirpichnikov MP, Gasparian ME, Dolgikh DA. Yagolovich AV, et al. Int J Mol Sci. 2022 Oct 21;23(20):12687. doi: 10.3390/ijms232012687. Int J Mol Sci. 2022. PMID: 36293545 Free PMC article.

3

Toxicity Evaluation and Controlled-Release of Curcumin-Loaded Amphiphilic Poly-N-vinylpyrrolidone Nanoparticles: In Vitro and In Vivo Models.

Luss AL, Bagrov DV, Yagolovich AV, Kukovyakina EV, Khan II, Pokrovsky VS, Shestovskaya MV, Gasparian ME, Dolgikh DA, Kuskov AN. Luss AL, et al. Among authors: yagolovich av. Pharmaceutics. 2023 Dec 19;16(1):8. doi: 10.3390/pharmaceutics16010008. Pharmaceutics. 2023. PMID: 38276486 Free PMC article.

4

Doxorubicin-Loaded Polyelectrolyte Multilayer Capsules Modified with Antitumor DR5-Specific TRAIL Variant for Targeted Drug Delivery to Tumor Cells.

Gileva A, Trushina D, Yagolovich A, Gasparian M, Kurbanova L, Smirnov I, Burov S, Markvicheva E. Gileva A, et al. Among authors: yagolovich a. Nanomaterials (Basel). 2023 Feb 27;13(5):902. doi: 10.3390/nano13050902. Nanomaterials (Basel). 2023. PMID: 36903780 Free PMC article.

5

Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH-DR5-B with Dual VEGFR2 and DR5 Receptor Specificity.

Yagolovich AV, Artykov AA, Isakova AA, Vorontsova YV, Dolgikh DA, Kirpichnikov MP, Gasparian ME. Yagolovich AV, et al. Int J Mol Sci. 2022 May 24;23(11):5860. doi: 10.3390/ijms23115860. Int J Mol Sci. 2022. PMID: 35682540 Free PMC article.

6

Amphiphilic Poly(N-vinylpyrrolidone) Nanoparticles Conjugated with DR5-Specific Antitumor Cytokine DR5-B for Targeted Delivery to Cancer Cells.

Yagolovich A, Kuskov A, Kulikov P, Kurbanova L, Bagrov D, Artykov A, Gasparian M, Sizova S, Oleinikov V, Gileva A, Kirpichnikov M, Dolgikh D, Markvicheva E. Yagolovich A, et al. Pharmaceutics. 2021 Sep 7;13(9):1413. doi: 10.3390/pharmaceutics13091413. Pharmaceutics. 2021. PMID: 34575490 Free PMC article.

7

Application of an Autoinduction Strategy to Optimize the Heterologous Production of an Antitumor Bispecific Fusion Protein Based on the TRAIL Receptor-Selective Mutant Variant in Escherichia coli.

Isakova A, Artykov A, Vorontsova Y, Dolgikh D, Kirpichnikov M, Gasparian M, Yagolovich A. Isakova A, et al. Among authors: yagolovich a. Mol Biotechnol. 2023 Apr;65(4):581-589. doi: 10.1007/s12033-022-00561-6. Epub 2022 Sep 12. Mol Biotechnol. 2023. PMID: 36094644

8

Corrigendum: Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL.

Artykov AA, Yagolovich AV, Dolgikh DA, Kirpichnikov MP, Trushina DB, Gasparian ME. Artykov AA, et al. Among authors: yagolovich av. Front Cell Dev Biol. 2022 Feb 14;9:820069. doi: 10.3389/fcell.2021.820069. eCollection 2021. Front Cell Dev Biol. 2022. PMID: 35237612 Free PMC article.

9

Dual targeting of DR5 and VEGFR2 molecular pathways by multivalent fusion protein significantly suppresses tumor growth and angiogenesis.

Isakova AA, Artykov AA, Plotnikova EA, Trunova GV, Khokhlova VА, Pankratov AA, Shuvalova ML, Mazur DV, Antipova NV, Shakhparonov MI, Dolgikh DA, Kirpichnikov MP, Gasparian ME, Yagolovich AV. Isakova AA, et al. Among authors: yagolovich av. Int J Biol Macromol. 2024 Jan;255:128096. doi: 10.1016/j.ijbiomac.2023.128096. Epub 2023 Nov 14. Int J Biol Macromol. 2024. PMID: 37972835

10

Assessment of the effects of amphiphilic poly (N‑vinylpyrrolidone) nanoparticles loaded with bortezomib on glioblastoma cell lines and zebrafish embryos.

Yagolovich AV, Kuskov AN, Kulikov PP, Bagrov DV, Petrova PA, Kukovyakina EV, Isakova AA, Khan II, Pokrovsky VS, Nosyrev AE, Stamati PC, Markvicheva EA, Gasparian ME, Spandidos DA, Tsatsakis AM. Yagolovich AV, et al. Biomed Rep. 2024 Jan 17;20(3):37. doi: 10.3892/br.2024.1725. eCollection 2024 Mar. Biomed Rep. 2024. PMID: 38343660 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

14 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year